ART Adherence, Resistance, and Long-term HIV Viral Suppression in Postpartum Women

被引：7

作者：

Redd, Andrew D. ^{[1
,2
]}

Mukonda, Elton ^{[3
]}

Hu, Nai-Chung ^{[3
]}

Philips, Tamsin K. ^{[3
]}

Zerbe, Allison ^{[4
]}

Lesosky, Maia ^{[3
]}

Hsiao, Nei-Yuan ^{[5
,6
]}

Clarke, William ^{[7
]}

Reynolds, Steven J. ^{[1
,2
,8
]}

Abrams, Elaine J. ^{[4
,9
]}

Myer, Landon ^{[3
,10
]}

机构：

[1] NIAID, Lab Immunoregulat, NIH, Baltimore, MD USA

[2] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA

[3] Univ Cape Town, Div Epidemiol & Biostat, Cape Town, South Africa

[4] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA

[5] Univ Cape Town, Dept Pathol, Div Med Virol, Cape Town, South Africa

[6] Groote Schuur Hosp, Natl Hlth Lab Serv, Cape Town, South Africa

[7] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA

[8] Rakai Hlth Sci Program, Kalisizo, Uganda

[9] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA

[10] Univ Cape Town, Sch Publ Hlth & Family Med, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa

来源：

OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 10期

基金：

美国国家卫生研究院;

关键词：

ART adherence; atiretrovirals; drug resistance; postpartum women; ANTIRETROVIRAL-THERAPY; PREVENTION; PREGNANCY;

D O I：

10.1093/ofid/ofaa346

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

HIV+ South African women who achieved viral suppression during routine antenatal care, but later experienced a viremic episode (viral load >1000 copies/mL), were examined for presence of antiretrovirals and classified as "nonadherers" or "suboptimal adherers." Women were tested for drug resistance mutations (DRMs) at several time points and underwent viral load testing 36-60 months postpartum. Suboptimal adherers were more likely to have DRM detected during their viremic episode (P = .03) and at a subsequent viremic time point (P = .05). There was no difference in levels of viral suppression 36-60 months later in women with DRM detected vs women who had no evidence of DRM (P = .5).

引用

页数：4

共 50 条

[31] Raltegravir is safely used with long-term viral suppression for HIV-infected patients on hemodialysis: a pharmacokinetic study
Yanagisawa, Kunio
Nagano, Daisuke
Ogawa, Yoshiyuki
Uchiumi, Hideki
Shigehara, Tetsuya
Saruki, Kazuhisa
Handa, Hiroshi
Araki, Takuya
Yamamoto, Koujirou
Nojima, Yoshihisa
AIDS, 2016, 30 (06) : 970 - 972
[32] Engagement in HIV care and viral suppression following changes in long-term opioid therapy for treatment for chronic pain
Silvis, Janelle
Rowe, Christopher L.
Dobbins, Sarah
Haq, Nimah
Vittinghoff, Eric
McMahan, Vanessa M.
Appa, Ayesha
Coffin, Phillip O.
AIDS AND BEHAVIOR, 2022, 26 (10) : 3220 - 3230
[33] Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study
Spagnuolo, V.
Galli, L.
Travi, G.
Cossarini, F.
Salpietro, S.
Gianotti, N.
Cinque, P.
Bossolasco, S.
Vinci, C.
Lazzarin, A.
Castagna, A.
INFECTION, 2010, 38 : 96 - 96
[34] Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
Ruiz, L
Martinez-Picado, J
Romeu, J
Paredes, R
Zayat, MK
Marfil, S
Negredo, E
Sirera, G
Tural, C
Clotet, B
AIDS, 2000, 14 (04) : 397 - 403
[35] Strenuous resistance to natural HIV-1 disease progression: viral controllers and long-term nonprogressors
Riva, Agostino
Vicenzi, Elisa
Galli, Massimo
Poli, Guido
FUTURE VIROLOGY, 2011, 6 (04) : 521 - 533
[36] Long-term survival of women diagnosed with cancer during pregnancy or postpartum
Cairncross, Zoe
Shack, Lorraine
Nelson, Gregg
Friedenreich, Christine
Ray, Joel
Sikdar, Khokan
Fell, Deshayne
Lisonkova, Sarka
McMorris, Carly
Bhatti, Parveen
Metcalfe, Amy
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2021, 50
[37] Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral therapy -: art. no. 10
Resino, S
Resino, R
Leon, JA
Bellon, JM
Martin-Fontelos, P
Ramos, JT
Gurbindo-Gutierrez, D
de Jose, MI
Ciria, L
Muñoz-Fernandez, MA
BMC INFECTIOUS DISEASES, 2006, 6 (1)
[38] Adherence to efavirenz therapy and maintenance of HIV viral suppression.
Saberi, P
Caswell, N
Amodio-Groton, M
Veltri, K
Alpert, P
PHARMACOTHERAPY, 2005, 25 (10): : 1454 - 1455
[39] Modeling long-term HIV dynamics and antiretroviral response - Effects of drug potency, pharmacokinetics, adherence, and drug resistance
Wu, HL
Huang, YX
Acosta, EP
Rosenkranz, SL
Kuritzkes, DR
Eron, JJ
Perelson, AS
Gerber, JG
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (03) : 272 - 283
[40] Long-term resistance to HIV infection in vertical HIV infection: Cytokine production, HIV isolation, and HIV phenotype define long-term resistant hosts
Vigano, A
Balotta, C
Trabattoni, D
Bricalli, D
Crupi, L
Palomba, E
Galli, L
Salvaggio, A
Fusi, ML
Ruzzante, S
Massironi, E
Colombo, MC
Principi, N
Galli, M
Clerici, M
PATHOBIOLOGY, 1997, 65 (04) : 169 - 176

← 1 2 3 4 5 →